Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Retained Earnings: 2021-2025

Historic Retained Earnings for Prime Medicine (PRME) over the last 3 years, with Sep 2025 value amounting to -$842.3 million.

  • Prime Medicine's Retained Earnings fell 30.60% to -$842.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$842.3 million, marking a year-over-year decrease of 30.60%. This contributed to the annual value of -$687.2 million for FY2024, which is 39.87% down from last year.
  • According to the latest figures from Q3 2025, Prime Medicine's Retained Earnings is -$842.3 million, which was down 6.39% from -$791.7 million recorded in Q2 2025.
  • Prime Medicine's Retained Earnings' 5-year high stood at -$171.4 million during Q4 2021, with a 5-year trough of -$842.3 million in Q3 2025.
  • For the 3-year period, Prime Medicine's Retained Earnings averaged around -$587.2 million, with its median value being -$592.4 million (2024).
  • Data for Prime Medicine's Retained Earnings shows a maximum YoY plummeted of 71.08% (in 2022) over the last 5 years.
  • Over the past 5 years, Prime Medicine's Retained Earnings (Quarterly) stood at -$171.4 million in 2021, then plummeted by 71.08% to -$293.2 million in 2022, then slumped by 67.58% to -$491.3 million in 2023, then tumbled by 39.87% to -$687.2 million in 2024, then tumbled by 30.60% to -$842.3 million in 2025.
  • Its Retained Earnings stands at -$842.3 million for Q3 2025, versus -$791.7 million for Q2 2025 and -$739.1 million for Q1 2025.